ArticleIranian journal of basic medical sciences2026
Harmaline improves diabetes-associated renal alterations in nicotinamide/streptozotocin-induced diabetic mice: Possible involvement of oxidative stress, inflammation, and renin-angiotensin system signaling.
Article in Iranian journal of basic medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Diabetic nephropathy (DN) is marked by structural and functional kidney damage, driven by oxidative stress, inflammation, and renin-angiotensin system (RAS) dysregulation. Harmaline (HAR), a β-carboline alkaloid with potent antioxidant and anti-inflammatory properties, is a promising multi-target therapeutic candidate. Materials and Methods: Twenty-four male mice were randomized into vehicle control (CO), diabetic (DI; nicotinamide 120 mg/kg+streptozotocin 65 mg/kg), diabetic treated with HAR (DI/HAR; 30 mg/kg), or diabetic treated with metformin (DI/MET; 150 mg/kg). After ten days, renal tissues and blood were analyzed for oxidative stress, inflammatory and RAS markers, microRNA expression, and histopathological alterations. Results: Harmaline reversed the changes in total oxidant status and malondialdehyde levels in kidney tissue of diabetic mice. Histopathological analysis showed significant improvement in kidney injury in diabetic mice receiving harmaline. Harmaline treatment decreased the expression of miR-125b, nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6). Also, in the antioxidant pathway, there was an increase in the levels of miR-200a, nuclear factor erythroid-related2 (Nrf2), and NAD(P)H quinone dehydrogenase 1 (Nqo1), and a decrease in ECH-like chelate-associated protein1 (Keap1) in kidney tissue. This treatment also decreased the expression of angiotensin-converting enzyme 1 (ACE1) and angiotensin II receptor 1 (AT1R), as well as angiotensin II levels. Conclusion: Harmaline confers renoprotection in experimental DN by simultaneously regulating oxidative stress, inflammatory signaling, and RAS pathways, supporting its potential as a multi-target therapeutic strategy. This study highlights HAR as a promising candidate for translational intervention in diabetic kidney disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.